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burdeniampaolo Niccoli, Francesco Burzotta, Leonarda Galiuto, Filippo Crea
n a variable proportion of patients with ST-segment elevation myocardial infarction
STEMI), primary percutaneous coronary intervention (PCI) achieves epicardial coronary
rtery opening but not myocardial reperfusion, a condition known colloquially as “no-reflow.”
he phenomenon has a multifactorial pathogenesis including distal embolization, ischemia-
eperfusion injury, and individual predisposition of coronary microcirculation to injury. Niccoli
nd colleagues review the risk factors for no-reflow and several options for preventing,
iagnosing, or treating the problem. They end by proposing a personalized management of
o-reflow based on the unique mechanisms that may be operative in each STEMI patient.CLINICAL RESEARCH LINICAL TRIALS293Both Pitavastatin and Atorvastatin Induce Plaque Regression in Post-ACS Patientsakafumi Hiro, Takeshi Kimura, Takeshi Morimoto, Katsumi Miyauchi, Yoshihisa Nakagawa,
asakazu Yamagishi, Yukio Ozaki, Kazuo Kimura, Satoshi Saito, Tetsu Yamaguchi, Hiroyuki Daida,
asunori Matsuzaki, for the JAPAN-ACS Investigators
his study by Hiro and colleagues evaluated whether the regressive effects of aggressive lipid-
owering therapy with atorvastatin in patients with acute coronary syndrome (ACS)
ould also occur with pitavastatin. Patients presenting with ACS who had a suitable
onculprit coronary stenosis were studied with intravascular ultrasound (IVUS) and
hen randomized to either atorvastatin 20 mg/day or pitavastatin 4 mg/day. IVUS
as repeated after approximately 9 months. Both drugs demonstrated a significant
nd similar reduction in the primary end point, nonculprit coronary plaque volume.
oth pitavastatin and atorvastatin can induce plaque regression in patients with ACS.(continued on page A-23)
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ENTERVENTIONAL CARDIOLOGY303Transfemoral or Transapical Aortic Valve Implantationominique Himbert, Fleur Descoutures, Nawwar Al-Attar, Bernard Iung, Gregory Ducrocq,
elphine Détaint, Eric Brochet, David Messika-Zeitoun, Fady Francis, Hassan Ibrahim, Patrick Nataf,
lec Vahanian
imbert and colleagues describe their experience with a strategy of offering either
ransfemoral or transapical aortic valve implantation to high-risk patients with severe aortic
tenosis. The transfemoral approach was used as the first option, and the transapical approach
as used when there was poor access from the iliac arteries or other contraindications. The
ransapical approach was needed in one-third of this cohort. The valve was implanted in 93%
f the cases with a hospital mortality of 10%. One-year survival was 78% overall, 81% in the
ransfemoral group, and 74% in the transapical group. One-year survival was significantly
ower in the first 25 patients, subsequently improving to 93%. Being able to offer either
ransfemoral or transapical aortic valve implantation can significantly and safely expand the
cope of patients with aortic stenosis who can be treated.EART FAILURE312Long-Term Results With Continuous Flow LVADrancis D. Pagani, Leslie W. Miller, Stuart D. Russell, Keith D. Aaronson, Ranjit John, Andrew J. Boyle,
ohn V. Conte, Roberta C. Bogaev, Thomas E. MacGillivray, Yoshifumi Naka, Donna Mancini,
. Todd Massey, Leway Chen, Charles T. Klodell, Juan M. Aranda, Nader Moazami, Gregory A. Ewald,
avid J. Farrar, O. Howard Frazier, for the HeartMate II Investigators
ulsatile left ventricular assist devices (LVADs) have significant limitations in their design
hat may be mitigated by continuous-flow rotary LVADs that are smaller and have a simpler
umping mechanism and that may be less prone to mechanical failure. Pagani and colleagues
eport their results with the use of the HeartMate II LVAD in almost 300 patients followed
or a minimum of 18 months. At the time of implantation, all subjects were United Network
f Organ Sharing status 1A or 1B. By the end of the 18 months, 79% of the subjects had
ither undergone transplantation, had their LVAD removed because of cardiac recovery, or
ad ongoing mechanical support. At 6 months, there were significant improvements in 6-min
alk and functional status. This continuous-flow LVAD provides effective hemodynamic
upport for at least 18 months.
ditorial Comment: Howard J. Eisen, Shelley R. Hankins, p. 322(continued on page A-25)
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MENETICS/GENOMICSMutations in ANKRD1 Linked to Both Hypertrophic and Dilated Cardiomyopathies325ousumi Moulik, Matteo Vatta, Stephanie H. Witt, Anita M. Arola, Ross T. Murphy,
illiam J. McKenna, Aladin M. Boriek, Kazuhiro Oka, Siegfried Labeit, Neil E. Bowles,
akuro Arimura, Akinori Kimura, Jeffrey A. Towbin
334akuro Arimura, J. Martijn Bos, Akinori Sato, Toru Kubo, Hiroshi Okamoto, Hirofumi Nishi,
aruhito Harada, Yoshinori Koga, Mousumi Moulik, Yoshinori L. Doi, Jeffrey A. Towbin,
ichael J. Ackerman, Akinori Kimura
wo articles in this issue report on the discovery of mutations in the cardiac ankyrin repeat
omain 1 gene, ANKRD1. The cardiac ankyrin repeat protein (CARP) is involved in muscle
tress responses such as stretch, injury, and hypertrophy. It is a nuclear transcription cofactor
nd is also found in the sarcomere, where it colocalizes with titin and myopalladin in the
disk. In the first article, Moulik and colleagues found mutations in ANKRD1 in 2% of
ubjects with dilated cardiomyopathies (DCM). In the second article, Arimura and colleagues
creened a large cohort of patients with hypertrophic cardiomyopathies and found 3 missense
utations accounting for 1% of HCM cases and 2 more mutations in the CARP-binding
omain of titin. An accompanying editorial by Mestroni explains how mutations in 1 gene
an present with such divergent phenotypes.ditorial Comment: Luisa Mestroni, p. 343ARDIAC IMAGING346Prospective ECG Gating Lowers the Radiation Dose With Similar Image Qualityianluca Pontone, Daniele Andreini, Antonio L. Bartorelli, Sarah Cortinovis, Saima Mushtaq,
rika Bertella, Andrea Annoni, Alberto Formenti, Enrica Nobili, Daniela Trabattoni, Piero Montorsi,
iovanni Ballerini, Piergiuseppe Agostoni, Mauro Pepi
rospective electrocardiogram (ECG) triggering may reduce the radiation exposure of
ultidetector computed tomography (MDCT) by only imaging during the part of the cardiac
ycle when the images should be of the highest quality. Retrospective ECG triggering uses a
ontinuous radiation exposure, but during the post-processing, many of the images are not
sed. Pontone and colleagues randomized subjects to MDCT with either prospective or
etrospective gating who then went on to invasive coronary angiography. The accuracy of
DCT was slightly lower in nonstented segments with prospective gating (93% compared
ith 96%), but was 98% in both groups in a patient-based analysis. The estimated radiation
ose was more than 3-fold lower with prospective gating. Prospective ECG-triggering
DCT has similar efficacy with a significantly lower radiation dose.(continued on page A-28)
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EIOMARKERS357Prognostic Value of Biomarkers During and After Acute Coronary Syndromes CMEai M. Eggers, Bo Lagerqvist, Per Venge, Lars Wallentin, Bertil Lindahl
ggers and colleagues studied the prognostic value of N-terminal pro-brain natriuretic
eptide (NT-proBNP), C-reactive protein (CRP), cardiac troponin I, and estimated
lomerular filtration rate in patients presenting with a non–ST-segment elevation acute
oronary syndrome (NSTE-ACS). Each biomarker was measured at presentation, at 6 weeks,
nd again at 6 months, with subjects followed for 5 years. NT-proBNP was the strongest
redictor of mortality at presentation and of the composite end point of death/acute
yocardial infarction at 6 weeks and 6 months. CRP was independently predictive at
months for the composite end point, but only 6-week NT-proBNP provided incremental
alue to established risk indicators. NT-proBNP is a strong risk predictor for patients with
STE-ACS, both at presentation and after stabilization.ditorial Comment: Christopher R. deFilippi, Stephen L. Seliger, p. 365
